Similar articles for PMID: 30842164

Year	Number of Results
2010	3
2011	4
2012	8
2013	7
2014	14
2015	20
2016	25
2017	24
2018	43
2019	51
2020	28
2021	25
2022	12
2023	3
2024	0

1

Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced EGFR Mutation-positive Non-small-cell Lung Cancer.

Ortega-Granados AL, Artal-Cortes Á, Aguiar-Bujanda D, Oramas J, Fírvida JL, DE Castro J, Fuentes JC, Gordo R, Galán R, Trigo J; ASPET Study Investigators. Ortega-Granados AL, et al. Anticancer Res. 2019 Mar;39(3):1317-1328. doi: 10.21873/anticanres.13244. Anticancer Res. 2019. PMID: 30842164

2

Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer.

Yamamoto N, Goto K, Nishio M, Chikamori K, Hida T, Maemondo M, Katakami N, Kozuki T, Yoshioka H, Seto T, Tajima K, Tamura T. Yamamoto N, et al. Int J Clin Oncol. 2017 Feb;22(1):70-78. doi: 10.1007/s10147-016-1039-0. Epub 2016 Sep 22. Int J Clin Oncol. 2017. PMID: 27659294 Free PMC article. Clinical Trial.

3

Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.

Lin YT, Chen JS, Liao WY, Ho CC, Hsu CL, Yang CY, Chen KY, Lee JH, Lin ZZ, Shih JY, Yang JC, Yu CJ. Lin YT, et al. Int J Cancer. 2019 Jun 1;144(11):2887-2896. doi: 10.1002/ijc.32025. Epub 2019 Jan 5. Int J Cancer. 2019. PMID: 30485437 Free article.

4

Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.

Sohn HS, Kwon JW, Shin S, Kim HS, Kim H. Sohn HS, et al. J Clin Pharm Ther. 2015 Dec;40(6):661-71. doi: 10.1111/jcpt.12332. Epub 2015 Nov 17. J Clin Pharm Ther. 2015. PMID: 26573867

5

Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations.

Aiko N, Shimokawa T, Miyazaki K, Misumi Y, Agemi Y, Ishii M, Nakamura Y, Yamanaka T, Okamoto H. Aiko N, et al. BMC Cancer. 2018 Oct 22;18(1):1012. doi: 10.1186/s12885-018-4911-7. BMC Cancer. 2018. PMID: 30348116 Free PMC article.

6

Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population.

Sutandyo N, Hanafi A, Jayusman M. Sutandyo N, et al. Zhongguo Fei Ai Za Zhi. 2019 Sep 20;22(9):562-567. doi: 10.3779/j.issn.1009-3419.2019.09.02. Zhongguo Fei Ai Za Zhi. 2019. PMID: 31526459 Free PMC article.

7

Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.

Chen YH, Chen YF, Chen CY, Shih JY, Yu CJ. Chen YH, et al. BMC Cancer. 2019 Oct 26;19(1):1006. doi: 10.1186/s12885-019-6140-0. BMC Cancer. 2019. PMID: 31655564 Free PMC article.

8

Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.

Zhang Q, Zhang X, Yan H, Jiang B, Xu C, Yang J, Chen Z, Su J, Wu YL, Zhou Q. Zhang Q, et al. Thorac Cancer. 2016 Nov;7(6):648-654. doi: 10.1111/1759-7714.12379. Epub 2016 Sep 1. Thorac Cancer. 2016. PMID: 27755835 Free PMC article.

9

Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.

Cho KM, Keam B, Kim TM, Lee SH, Kim DW, Heo DS. Cho KM, et al. Korean J Intern Med. 2015 Nov;30(6):891-8. doi: 10.3904/kjim.2015.30.6.891. Epub 2015 Oct 30. Korean J Intern Med. 2015. PMID: 26552465 Free PMC article.

10

Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors.

Aguiar-Bujanda D, Dueñas-Comino A, Saura-Grau S, Ros-Sanjuan L, Blanco-Sanchez MJ, Hernandez-Sosa M, Mori-De Santiago M, Galvan-Ruiz S, Lorenzo-Barreto JE, Vargas-Prado AM, Bohn-Sarmiento U. Aguiar-Bujanda D, et al. Oncol Res Treat. 2018;41(12):755-761. doi: 10.1159/000492344. Epub 2018 Nov 13. Oncol Res Treat. 2018. PMID: 30419558

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

241 results

Results by year